| Patient | Eva Perón |
|---|---|
| Date of birth | 1919-05-07 |
| Identifiers | MRN HR-ML025-SYN-TD; SSN (made up) 000-25-7316 |
| Document date | 1951-08-17 |
| Author | Lucía Barragán, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Review three months after treatment, with the PET-CT result. [S]
Ms. Perón returns three and a half months after finishing treatment. Her PET-CT a week ago showed a complete metabolic response, with no uptake in the cervix, nodes or elsewhere, and Dr. Osei-Bonsu's examination last month found no tumor. The estradiol patch and progesterone stopped the hot flashes and night sweats within a few weeks. She uses the dilator three times a week; intercourse is comfortable with a lubricant. Her energy is nearly back, she has regained weight, and she is working full days again. She has had no bleeding, pelvic or back pain, or leg swelling. [S]
| Element | Detail |
|---|---|
| PET-CT | Complete metabolic response a week ago |
| Menopause care | Symptoms controlled on estradiol and progesterone |
| Dilator | Three times a week |
| Work | Full days again |
| Scores | PHQ-9 4; GAD-7 4; pain 0 |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy nearly normal; weight regained; no night sweats |
| Gastrointestinal | Negative | Bowels normal; no rectal bleeding |
| Genitourinary | Negative | No bleeding or discharge; no urinary symptoms |
| Musculoskeletal | Negative | No back or pelvic pain; no leg swelling |
| Psychiatric | Negative | Mood good; no thoughts of self-harm |
5 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Ferrous sulfate 325 mg (65 mg elemental iron) oral tablet, one tablet by mouth once daily, with vitamin C-rich food or juice, apart from tea and dairy | One tablet by mouth once daily | Oral route | 1951-02-09 to 1951-08-17 | completed | S |
| Acetaminophen 500 mg oral tablet, one or two tablets by mouth every 6 hours when needed for pelvic pain, no more than 6 tablets a day | One or two tablets every 6 hours when needed, no more than 6 a day | Oral route | 1951-02-09 | active | S |
| Nitrofurantoin (monohydrate and macrocrystals) 100 mg oral capsule, one capsule by mouth twice daily with food for 5 days | One capsule twice daily with food for 5 days | Oral route | 1951-03-27 to 1951-03-31 | completed | S |
| Cisplatin 40 mg/m2 (64 mg) intravenous infusion once weekly for five weeks during pelvic radiation, with hydration and antiemetic premedication in the infusion center | 64 mg intravenously once weekly for five doses | Intravenous route | 1951-03-09 to 1951-04-06 | completed | S |
| Ondansetron 8 mg oral tablet, one tablet by mouth every 8 hours when needed for nausea in the days after cisplatin | One tablet every 8 hours when needed for nausea | Oral route | 1951-03-09 to 1951-04-10 | completed | S |
| Loperamide 2 mg oral capsule, two capsules after the first loose stool, then one after each loose stool, no more than 8 a day | Two capsules after the first loose stool, then one after each, no more than 8 a day | Oral route | 1951-03-09 to 1951-05-04 | completed | S |
| Estradiol 0.1 mg per day transdermal patch, one patch changed twice weekly | One patch changed twice weekly | Topical route | 1951-05-18 | active | S |
| Progesterone 100 mg oral capsule, one capsule by mouth nightly, to protect any remaining endometrium while on estradiol | One capsule by mouth nightly | Oral route | 1951-05-18 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1951-08-17 | Body height | 165 | cm | S |
| 1951-08-17 | Body weight | 52.4 | kg | S |
| 1951-08-17 | Body mass index (BMI) [Ratio] | 19.2 | kg/m2 | S |
| 1951-08-17 | Systolic blood pressure | 108 | mm[Hg] | S |
| 1951-08-17 | Diastolic blood pressure | 68 | mm[Hg] | S |
| 1951-08-17 | Heart rate | 74 | /min | S |
| 1951-08-17 | Respiratory rate | 14 | /min | S |
| 1951-08-17 | Body temperature | 36.6 | Cel | S |
| 1951-08-17 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1951-08-17 | Hemoglobin [Mass/volume] in Blood | 12.6 | g/dL | 11.6-15 g/dL | Normal | S |
| 1951-08-17 | Ferritin [Mass/volume] in Serum or Plasma | 48 | ng/mL | A ferritin of 30 ng/mL or less indicates iron deficiency | Normal | S |
| 1951-08-17 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 0 | {score} | S | ||
| 1951-08-17 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 4 | {score} | S | ||
| 1951-08-17 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 4 | {score} | S |
Vital signs recorded on 1951-08-17; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; weight 52.4 kg; blood pressure 108/68 |
| Lymph nodes | No inguinal or supraclavicular nodes |
| Pelvic | Cervix small, pale and smooth, with radiation changes and no mass; upper vagina mildly narrowed; rectovaginal examination: parametria soft, without nodularity |
| Legs | No swelling |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Bleeding after intercourse and between periods, with heavier periods, for about four months, with tiredness and a dull pelvic ache. Never had cervical screening. Speculum examination shows a friable, exophytic mass about 4 cm across on the cervix that bleeds on contact. Punch biopsy, HPV test and cytology taken; urgent gynecologic oncology consultation booked | resolved | confirmed | N93.8 | S — Synthetic presenting problem linked to her documented abnormal bleeding with anemia; superseded by the diagnosis at the consultation. |
| Iron deficiency anemia from chronic blood loss: hemoglobin 9.4 g/dL, mean cell volume 72 fL, ferritin 6 ng/mL, with tiredness and breathlessness on stairs | resolved | confirmed | D50.0 | S — Synthetic modern finding linked to her documented anemia from vaginal bleeding. |
| Invasive squamous cell carcinoma of the cervix, HPV 16 positive: an exophytic tumor about 4.5 cm across with clinical involvement of the left parametrium, not reaching the pelvic wall; pelvic MRI and PET-CT ordered for FIGO 1943 staging. Synthetic modern episode linked to her documented cervical cancer | active | confirmed | C53.9 | S — Synthetic modern diagnosis made at the gynecologic oncology consultation. |
| Acute cystitis during pelvic chemoradiation: two days of new burning, urgency and cloudy urine on top of mild radiation frequency, without fever or flank pain; urine dipstick positive for leukocyte esterase and nitrite; culture grew Escherichia coli sensitive to nitrofurantoin; neutrophil count and kidney function normal; resolved | resolved | confirmed | N30.00 | S — Synthetic acute infection; not a historical claim. |
| Ovarian failure after pelvic radiation, with hot flashes, night sweats, poor sleep and vaginal dryness two weeks after treatment; FSH 72 mIU/mL and estradiol 14 pg/mL | active | confirmed | E89.41 | S — Synthetic expected effect of pelvic chemoradiation. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Imaging | FDG PET-CT | At staging; about three months after chemoradiation | Up to date | A week ago: complete metabolic response |
| Examination | Pelvic, speculum and rectovaginal examination | At diagnosis; every three to six months for two years after treatment | Completed today | No tumor; parametria soft; upper vagina mildly narrowed |
| Laboratory | Blood count (hemoglobin, white cells, platelets) | About one month after starting oral iron, then every three months for a year; weekly during chemoradiation | Completed today | Hemoglobin 12.6 g/dL |
| Laboratory | Ferritin | At the end of the iron course | Completed today | 48 ng/mL; iron stopped |
| Examination | Treatment side effects (bowel, bladder, skin, nausea, hearing, nerve symptoms) | At each visit | Completed today | No late bowel or bladder effects; no hearing loss or neuropathy |
| Survey | Pelvic pain score and analgesic safety (no anti-inflammatory painkillers with cisplatin) | Every visit | Completed today | 0 of 10 |
| Survey | PHQ-9 and GAD-7 | At diagnosis, before treatment, at mid-treatment, at the end of treatment, and in follow-up | Completed today | PHQ-9 4 (item 9 scored 0), GAD-7 4 |
| Self-management | Vaginal dilator use | Starting two to four weeks after radiation, three times a week | Completed today | Three times a week; intercourse comfortable |
| Medication safety | Hormone therapy safety (blood pressure, clot symptoms) and symptom control | At the start and every visit | Completed today | Blood pressure 108/68; no clot symptoms; symptoms controlled |
| Referral | Survivorship care plan and gynecologic oncology follow-up | From the end of treatment | Completed today | Written plan in Spanish given; gynecologic oncology next month |
| Referral | Oncology social worker and spiritual care | Through treatment and survivorship | Completed today | Monthly social work visits |
Goal progress:
Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Cervical Cancer (Version 1.2027); Patient-Clinician Communication: American Society of Clinical Oncology Consensus Guideline (2017); Management of Anxiety and Depression in Adult Survivors of Cancer: ASCO Guideline Update (2023); CMID: Clinical Monitoring Intelligence Database, anemia monograph (2026)
Follow-up: Gynecologic oncology review next month. Preventive visit in about a month. Next scheduled visit 1951-09-21: periodic adult preventive visit after cancer treatment. [S]